Skip to main content
All lobbying filings

EDWARDS LIFESCIENCES, LLC

EDWARDS LIFESCIENCES, LLC filed a Q1 report for EDWARDS LIFESCIENCES LLC on April 18, 2025.

Lobbying for EDWARDS LIFESCIENCES LLC

All filings by EDWARDS LIFESCIENCES, LLC · Everything EDWARDS LIFESCIENCES LLC has reported

 Filing · LD-2 quarterly report Q1 report
Reporting period
1st Quarter 2025
Jan 1 - Mar 31 · Posted Apr 18, 2025
Expenses
$350,000
What this organization spent lobbying with its own staff. Reported using the LDA's own definitions (method A): the three LDA methods count different costs, so an expenses figure is not comparable across filers that used different ones.
Client based in
California

Official filing document

 Government bodies contacted 5

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

 Lobbying activity 5

Ensuring Patient Access to Critical Breakthrough Products (H.R.1691 S.5349) Transitional Coverage for Emerging Technologies (TCET) Guidance Policies promoting medical innovation Heart Valve Disease Awareness FDA Reauthorization for 2022/FDA User Fees Diversity in Clinical Trials Coverage with Evidence Development

CMS Coverage Policies for Medical Devices CMS Payment Policies for Medical Devices Ensuring Patient Access to Critical Breakthrough Products (H.R.1691/S.5349) Heart Valve Disease Awareness National Coverage Determination for TAVR Coverage of Transcatheter Tricuspid Valve Replacement Diversity in Clinical Trials Coverage with Evidence Development

Corporate Tax Reform Proposals

Veterans Access to MedTech

 Bills named in this filing 2
  • H.R. 1691
    Ensuring Patient Access to Critical Breakthrough Products Act of 2024
  • S. 5349
    Ensuring Patient Access to Critical Breakthrough Products Act of 2024

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.

Report a problem